Patent · US Active

Prevention of HIV-infection

US10765674B2 · kind B2 · utility

1Cited by

0References

24Claims

0Family size

Assignee

Janssen Sciences Ireland Unlimited Company · IE

Inventors

Lieven Elvire Colette Baert · Brugge, BE
Paulus Joannes Lewi · Turnhout, BE
Jan Heeres · Vosselaar, BE

Key dates

Filing date	Jun 13, 2016
Grant date	Sep 8, 2020
Priority date	—
Expiry date	Sep 26, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.